Biomerica, Inc. · NASDAQ:BMRA
Biomerica — Investor Presentation (March 2026)
26 slides from Biomerica's investor presentation, March 2026
Slide 1: Investor Presentation Mar 2026
Investor Presentation Mar 2026 Copyright © 2025 Biomerica. All Rights Reserved
Slide 2: Forward-Looking Statement
Forward-Looking Statement The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this presentation (as well as information included in oral statements or other written statements made or to be made by Biomerica) c
Slide 3: Who We Are
Who We Are Depth of Scientific Leadership Global Biomedical Company US Members of the Rome Develops, patents, Our customers Foundation Clinical studies lead manufactures & markets in USA by principal investigators who advanced diagnostics for set GI “treatment guidelines” use in Clinical lab, Mayo M
Slide 4: Leadership, Board & Depth in Science
Leadership, Board & Depth in Science Management Scientific Advisory Board inFoods® Principal Investigators ZACK IRANI-COHEN Principal Investigators or • Chief Executive Officer & Chairman Collaborators for: • Previous CEO & Chairman of Lancer DOUGLAS DROSSMAN, MD WILLIAM CHEY, MD, AGAF, Orthodontics
Slide 5: Transforming Diagnostics into Personalized Therapies
Transforming Diagnostics into Personalized Therapies Leveraging diagnostic expertise to transition into diagnostic-guided therapeutics Specialty diagnostics enabling early Disruptive patented technology disease detection and monitoring platform enabling diagnostic therapies Two FDA, CE, CFDA registe
Slide 6: inFoods IBS – Precision Medicine for IBS
inFoods® IBS – Precision Medicine for IBS Example of Patient-Specific Results Measures elevated immune response for a disease specific panel of foods to determine which foods are above normal range for a patient 35 patents issued and clinically tested laboratory test that identifies trigger foods th
Slide 7: Irritable Bowel Syndrome (IBS) is Very Common and Costly
Irritable Bowel Syndrome (IBS) IBS is the #1 most common diagnosis made by IBS is the #7 most common diagnosis made by is Very Common gastroenterologists1 all physicians1 and Costly IBS sufferers have 74% IBS patients visit doctors 3x more direct healthcare more than non-IBS patients costs vs. non-I
Slide 8: IBS Market Opportunity $30B+
M IBS Market Opportunity Significant Today and Growing D C 40 Million IBS Patients in the US $30B+ 1/3 IBS-C (Constipation) 1/3 IBS-D (Diarrhea) 1/3 IBS-M (Mixed: Alternates C+D) U.S. TAM1 IBS = recurrent abdominal pain & change in bowel habits ~16 M I L L I O N US IBS Patients: seeking consistent p
Slide 9: inFoods IBS: Clinical Study Design Summary
inFoods IBS: Clinical Study Design Summary Randomized Double Blinded Sham controlled Patient is inFoods positive to: Blueberries & Almonds 1:1 Treatment Arm Placebo Arm Eliminates Eliminates Blueberries & Almonds Raspberries & Walnuts (if negative and same consumption) Copyright © 2025 Biomerica. Al
Slide 10: Significant Symptom Improvement
Significant Symptom Improvement Copyright © 2025 Biomerica. All Rights Reserved 10
Slide 11: First Therapeutic Approach for IBS-M Patients
First Therapeutic Approach for IBS-M Patients P=0.02 P=0.01 Copyright © 2025 Biomerica. All Rights Reserved
Slide 12: inFoods Delivers Global Therapy Endpoints
inFoods Delivers Global Therapy Endpoints Significant Symptom Relief vs Placebo Treatment Arm Vs. Placebo Arm Significant symptom relief seen across multiple IBS subtypes SGA P-value of 0.007 for improvement in the Subject’s Global Assessment of Relief (SGA) endpoint for all patient subtypes as a gr
Slide 13: FDA Approved IBS Drugs are High Cost & Low Relief with Safety Limitations
FDA Approved IBS Drugs are High Cost & Low Relief with Safety Limitations Efficacy: FDA Treatment Placebo Monthly Annualized Indication Drug Treatment Limitations Approval Response Response Cost U.S. Sale minus Placebo • Diarrhea side Linzess 2012 20% - 34% 6% - 27% 7% - 14% $467 $1,963M effect (20%
Slide 14: Published in Gastroenterology: Primary Endpoint Met
Published in: Primary Endpoint Met June 2025 issue of Gastroenterology Gastroenterology is the leading GI publication Copyright © 2025 Biomerica. All Rights Reserved 14
Slide 15: inFoods IBS: $300 Medicare Payment Rate
inFoods IBS: $300 Medicare Payment Rate Guidelines + Reimbursement = Market Opportunity AGA Clinical Guidelines Clinical Data CMS Payment rate "Prioritize dietary changes as 59.6% Pain reduction $300 Medicare rate (Effective Jan first-line treatment for all IBS (Gastroenterology, 2025) 1, 2026) pati
Slide 16: inFoods IBS: Whole Blood & Self Collection
inFoods IBS: Whole Blood & Self Collection inFoods® IBS: Validated for Use with Simple Finger Stick Whole Blood Collection Technology Finger stick (capillary) patient whole blood samples simplify sample collection and facilitate wider access to the test. Doctor’s Office Collection Any trained medica
Slide 17: Launch of inFoods IBS
Launch of inFoods IBS Relationship with Gastro Health (GH): A leading gastroenterology group with over 390 employed GI physicians. A leader in advanced innovation and technology in GI patient care . inFoods IBS is now integrated into GH patient systems to facilitate doctors’ “one click” ordering for
Slide 18: Platform Technology: inFoods Development Pipeline
Platform inFoods® Technology: Development Pipeline Product End CLIA LDT Pivotal Trial & IP & Data FDA Sub Q Dev. R&D Point Trial Launch FDA Approval 18 Foods Irritable Bowel Syndrome (IBS) Functional Gastrointestinal 37 Foods Functional Dyspepsia Disorders 19 Foods GERD disease Gastrointestinal 58 F
Slide 19: Specialty Diagnostics
Specialty Diagnostics Copyright © 2025 Biomerica. All Rights Reserved 19
Slide 20: 2026 Growth Opportunity - H. pylori
2026 Growth Opportunity - H. pylori Status: Biomerica received FDA 510K clearance Detects H. pylori Antigen Gastric Cancer: Gastric cancer is the 3rd most common cause of cancer related death in the world. Over 80% of gastric cancers are attributed to H. pylori infection. In 2017, the World Health O
Slide 21: Colorectal Disease Test: EZ Detect
Colorectal Disease Test: EZ Detect EZ Detect is a 2-minute, at-home test for Quick & Simple: the determination of fecal occult blood, an early warning sign of colorectal cancer (CRC) and other colorectal diseases. No Stool Handling 1 2 3 Interpretation Negative Positive Positive Any color in the tes
Slide 22: Low Cost Compared to Other Screening Tests & Same Consequence
Low Cost Compared to Other Screening Tests & Same Consequence Value EZ DetectTM Cologuard®1 FIT1 List Price $18 $649 $22 Accuracy 93.2% 86.6% 94.7% Specificity 99.2% 86.6% 94.9% (vs. all negative findings on Colo colonoscopy/sigmoidoscopy) (124 / 125) (7936 / 9167) (8695 / 9167) Sensitivity 72.9% 92
Slide 23: Prostate (PSA) Screening Test
Prostate (PSA) Screening Test The Fortel® Prostate (PSA) Screening test is a simple at-home visual test to detect elevated levels of Prostate Specific Antigen (PSA) using a finger prick blood sample Laboratory accuracy in the comfort of your home Results in 10 minutes Prostate (PSA) screening made e
Slide 24: Laboratory Accuracy
Laboratory Accuracy Reference Method Clinical Study #1 Performance vs. Reference Method Positive Negative Total Fortel® (Immulite 2000/ Abbott Axsym Total Prostate Positive 80 4 84 PSA /Roche E170 tests) (PSA) Screening Negative 0 77 77 Sensitivity: 100% Test Total 80 81 161 Specificity: 95% • Clini
Slide 25: Insurance reimbursement & distribution
Insurance reimbursement & distribution New multi-year exclusive distribution agreement with leading UAE healthcare company recently signed In discussions with other governments for Insurance Reimbursement in UAE and other MENA countries Fortel® Prostate PSA received approval from the Kingdom of Saud
Slide 26: Leveraging Our Unique Technology
Disruptive Patented Platform Technology redefining the GI Market Addressing the large need for IBS patients and then targeting multiple other diseases inFoods Model is Unique Leveraging Benefits Patient / Physician / Insurer Our Unique Broad IP Protection Robust patent portfolio (35 issued patents;